Peptide therapy refers to restoring the amount of peptides to stimulate the cellular regeneration system in the body, and can be an excellent complement to small molecule and biotherapeutics as a treatment option under certain conditions. The most common uses of peptide therapy are to help build muscle and reduce fat, increase energy, improve sexual function, and reduce gastrointestinal and musculoskeletal inflammation. The most common prescription peptide combinations naturally boost growth hormone for better recovery. Peptides were initially used only for diagnostics and hormone therapy; however, as technology has advanced, they are now also widely used to treat cancer and chronic metabolic diseases. Peptides are also used in cosmeceutical operations to slow down the skin's aging process.
This report contains market size and forecasts of Peptide Therapy in global, including the following market information:
Global Peptide Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Peptide Therapy Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Peptide Therapy companies in 2021 (%)
The global Peptide Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Parenteral Route of Administration Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Peptide Therapy include Eli Lilly, AstraZeneca, Merck, Ipsen, Novo Nordisk, Teva Pharmaceutical Industries, Abbott Laboratories, Sanofi and J & J, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Peptide Therapy manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Peptide Therapy Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Peptide Therapy Market Segment Percentages, by Type, 2021 (%)
Parenteral Route of Administration
Mucosal Route of Administration
Oral Route of Administration
Transdermal Route of Administration
Global Peptide Therapy Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Peptide Therapy Market Segment Percentages, by Application, 2021 (%)
Cancer
Cardiovascular Diseases
Gastrointestinal Disorders
Metabolic Disorders
Others
Global Peptide Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Peptide Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Peptide Therapy revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Peptide Therapy revenues share in global market, 2021 (%)
Key companies Peptide Therapy sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Peptide Therapy sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
AstraZeneca
Merck
Ipsen
Novo Nordisk
Teva Pharmaceutical Industries
Abbott Laboratories
Sanofi
J & J
Novartis
Takeda
Ferring
AbbVie
Heinis
Hemmo
Emcure Pharmaceutical
Cipla
Gland Pharma
Troikaa Pharmaceuticals
Biological E